Rituximab Myths: — Vaccines, Immunity and 'Permanent Damage'

B-cell recovery is gradual and varies between individuals and by the regimen used. ASCO and ESMO guidance notes that recovery typically occurs over months following the last dose, though immunoglobulin levels — the antibodies your B-cells produce — may take longer to return to normal. Your team will monitor your blood counts and can give you a clearer picture of how your recovery is progressing. If you are asking because you want to plan a vaccine, ask your oncologist for the right timing window rather than waiting and guessing.

The seasonal influenza vaccine is an inactivated vaccine, not a live one, so it is not automatically ruled out. However, how well your body responds depends on how many B-cells are available to generate an immune response at the time. Your team may advise on timing — either before treatment begins or at a point where your immune response is likely to be stronger. Ask your oncologist specifically about the flu vaccine and the best time to have it, rather than skipping it on the assumption it cannot be given.

Hair loss is not a typical side effect of rituximab. It is a well-known side effect of cytotoxic chemotherapy, and because rituximab is sometimes given alongside chemotherapy agents, people in those combination regimens may experience hair loss — but this comes from the chemotherapy component, not from rituximab itself. Rituximab's side effects are primarily related to infusion reactions and the period of reduced immunity from B-cell depletion. Ask your oncologist which drugs are in your specific regimen and which side effects come from which drug.

Normal contact with family is generally fine. The specific precaution is around anyone who has recently had a live vaccine — such as young children who have just received the rotavirus or chickenpox vaccine — because those individuals can shed small amounts of vaccine virus. Your team will advise on how long to take precautions in that situation. For day-to-day living, the more practical concern is avoiding people with active infections and washing hands regularly, especially during treatment and in the months of B-cell recovery that follow.

It is described as both, depending on the context. Rituximab is a targeted therapy in the sense that it targets a specific protein — CD20 — rather than attacking cells indiscriminately. It is also classified as a monoclonal antibody immunotherapy because it works by directing your immune system to destroy B-cells that carry CD20 on their surface. What it is not is cytotoxic chemotherapy. The distinction matters because the side effect profile, the way it is monitored, and the recovery pathway are all different from conventional chemotherapy drugs.